SalMar strengthens ocean-based fish farming and changes CEO
Gustav Witzøe will take over as CEO of SalMar effective 21 October 2019. From this date the current CEO, Olav Andreas Ervik, will become managing director of the new subsidiary SalMar Ocean AS and responsible for the company's ventures in ocean-based fish farming.
SalMar's initiatives in ocean-based fish farming has to date been organised as a business area within SalMar and headed by Gustav Witzøe. These activities will now be transferred to a subsidiary which Ervik wanted to lead.
Both Witzøe and Ervik emphasise that this change will ensure continuity in management and that it is a logical consequence of SalMar's ambition to lead in the development of ocean-based fish farming.
The Board of Directors considers this a good foundation for the continued positive development of SalMar, both within ocean-based and conventional fish farming.For further information, please contact:
Atle Eide, Chair of the Board in SalMar ASA
Telephone: +47 911 52 977
Email: [email protected]
Gustav Witzøe, CEO in SalMar ASA
Telephone: +47 911 47 834
Email: [email protected]
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
More News in Finance
As Biotechnology businesses, Radius Health Inc. (NASDAQ:RDUS) and Corcept Therapeutics Incorporated (NASDAQ:CORT), are affected by contrast. This especially applies to their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation. Earnings and Valuation
Equities analysts expect Corcept Therapeutics Incorporated (NASDAQ:CORT) to announce sales of $77.59 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Corcept Therapeutics' earnings. The highest sales estimate is $79.10
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) and Corcept Therapeutics Incorporated (NASDAQ:CORT) compete with each other in the Biotechnology sector. We will analyze and contrast their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation. Valuation and
Investors sentiment decreased to 1.34 in 2019 Q2. Its down 0.30, from 1.64 in 2019Q1. It fall, as 24 investors sold ITRI shares while 55 reduced holdings. 36 funds opened positions while
In the background meanwhile, traders were waiting on an expected key vote in the UK Parliament at the weekend and digesting mixed economic data out of China overnight. Yet otherwise, the market spotlight
Sunday، 20 October 2019 09:51 PM Federal Reserve officials have said little to take a third straight interest-rate cut off the table when they meet this month. They also haven't said much about what they'll